US-based MedTech testing, clinical and regulatory consulting firm NAMSA has agreed to acquire the US medical device testing operations of WuXi AppTec.
WuXi AppTec is a China-based company providing a portfolio of R&D and manufacturing services to pharmaceutical and life science industries.
Under the terms of the agreement, NAMSA will acquire WuXi AppTec medical device testing facilities in Minnesota and Georgia, with all other operations remaining unaffected.
The company will continue to provide services to its customers through its integrated Contract Research, Development, and Manufacturing Organisation (CRDMO) platform.
NAMSA CEO André-Michel Ballester said: “We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients.
“NAMSA and WuXi AppTec’s Medical Device Testing Operations have different areas of expertise but serve the same client base and will enhance the client experience by combining capabilities.
“Together, we look forward to accelerating MedTech innovation and helping Sponsors deliver life-saving medical technology throughout the world.”
According to NAMSA, the MedTech industry is facing strict regulatory and clinical evidence requirements, which may delay development, increase costs, and slow market entry.
Its strategic outsourcing and in-house services could MedTech innovators mitigate risk, shorten time to market and enhance stakeholder value.
With operations across Asia, Europe, and North America, WuXi AppTec provides a portfolio of R&D and manufacturing services pharmaceutical and life sciences industries.
Both NAMSA and WuXi AppTec will work closely to enable a smooth transition for employees and customers.
Evercore served as the financial advisor, and Wilson Sonsini Goodrich & Rosati as the legal advisor to WuXi AppTec, on this transaction.
WuXi AppTec co-CEO Steve Yang said: “This transaction supports our strategic business portfolio optimization, sharpens our focus on and positions us to invest further in our core CRDMO business in the US and elsewhere, and strengthens our unique CRDMO model for pharmaceutical products.
“It will enhance business synergies across research, development and manufacturing services to better meet the evolving needs of our customers globally. Together, we can realize our vision that ‘every drug can be made and every disease can be treated.”
